← Leaderboards
Chunru Lin
University Of California, San Diego
$7,032,732
Attributed
$7,032,732
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,032,732 · 5
By mechanism
R01$6,195,780 · 3
R00$746,952 · 1
K99$90,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Ju Chen$42,409,674
- Michael G Rosenfeld$73,496,650
- Christopher K Glass$71,096,171
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMediatingMolecularMalignant Breast NeoplasmGenetic TranscriptionUntranslated RnaMammary GlandTherapeutic TargetPlayToxic EffectPathway InteractionsTriple-Negative Invasive Breast CarcinomaResistanceSignal TransductionEventTargeted TreatmentAttenuatedMalignant NeoplasmsBreast Cancer PatientResponseSignal PathwayCancer InitiationInnovationImmunotherapy
Grant awards (20)
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy$459,875
R01 · FY2025 · CA · contact PI
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy$429,937
R01 · FY2024 · CA · contact PI
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy$443,515
R01 · FY2023 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$361,866
R01 · FY2023 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$358,680
R01 · FY2023 · CA · contact PI
Targeting Small Nucleolar RNA Augments Immunotherapeutic Efficacy$483,568
R01 · FY2022 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$358,680
R01 · FY2022 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$325,680
R01 · FY2022 · CA · contact PI
Long Noncoding RNA Advocates Immune Resistant Microenvironment$375,816
R01 · FY2021 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$366,000
R01 · FY2021 · CA · contact PI
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer$377,397
R01 · FY2020 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$366,000
R01 · FY2020 · CA · contact PI
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer$366,075
R01 · FY2019 · CA · contact PI
Development of Long non-coding RNA-directed Target Therapy for Triple-Negative Breast Cancer$366,000
R01 · FY2019 · CA · contact PI
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer$380,586
R01 · FY2018 · CA · contact PI
Significance of Inhibiting Long Non-coding RNAs in Advanced Breast Cancer$376,105
R01 · FY2017 · CA · contact PI
Nuclear Architecture, NcRNAs and Epigenetics in Transcriptional Regulation by ER$248,984
R00 · FY2015 · DK · contact PI
Nuclear Architecture, NcRNAs and Epigenetics in Transcriptional Regulation by ER$248,984
R00 · FY2014 · DK · contact PI
Nuclear Architecture, NcRNAs and Epigenetics in Transcriptional Regulation by ER$248,984
R00 · FY2013 · DK · contact PI
Nuclear Architecture, NcRNAs and Epigenetics in Transcriptional Regulation by ER$90,000
K99 · FY2012 · DK · contact PI